U.S. Markets closed

Natera, Inc. (NTRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
56.65+0.95 (+1.71%)
At close: 04:00PM EDT
56.32 -0.33 (-0.58%)
After hours: 05:28PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close55.70
Bid56.45 x 900
Ask59.16 x 900
Day's Range54.33 - 56.71
52 Week Range27.35 - 59.75
Avg. Volume1,402,732
Market Cap6.177B
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-2.84
Earnings DateMay 03, 2023 - May 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.00
  • Business Wire

    New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma

    AUSTIN, Texas, March 22, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in patients with stages III-IV melanoma. The full study can be found here.

  • Business Wire

    Natera Announces Commercial Payor Coverage for Signatera™

    AUSTIN, Texas, March 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring.

  • Zacks

    Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

    Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?